Trigeminal Neuralgia & Functional Radiosurgery

1.Technique, dose, and outcomes

For classic, medically refractory trigeminal neuralgia, radiosurgery delivers a high single dose to the trigeminal root entry zone or a more distal retrogasserian cisternal segment. A common Gamma Knife technique uses a single 4-mm shot with a maximum dose of 80–90 Gy, but the exact target along the nerve and dose are linked decisions. Initial pain relief is similar whether the anterior retrogasserian segment or the root entry zone is targeted, while the more proximal target carries higher rates of hypesthesia and greater brainstem exposure, and long-term relief favors the anterior target. Elongating the treated nerve with a second isocenter does not improve relief and increases sensory toxicity, so a single 4-mm isocenter is standard. Outcomes are reported on the Barrow Neurological Institute (BNI) pain scale: initial adequate relief (BNI I–IIIb, often off or on reduced medication) occurs in roughly 70–90%, with a characteristic latency of weeks to a few months and gradual recurrence such that freedom from pain without medication is roughly 70% at 3 years and 50% at 5 years, falling to 30–45% at 10 years. The principal toxicity is facial numbness / sensory dysfunction, commonly reported in roughly 10–30% and more frequent at higher dose, with longer treated nerve length, and after retreatment. Brainstem exposure should follow the institution's validated TN technique rather than borrowing tumor-SRS point constraints. Repeat SRS can restore pain control in most recurrences, with roughly 73% reaching BNI III or better, but new trigeminal sensory dysfunction follows in about 44% and cumulative maximum dose across both treatments should be tracked explicitly. Anesthesia dolorosa remains rare at about 1%.

SRS is the only TN intervention that is non-ablative at the moment of treatment and creates no immediate lesion: relief is delayed precisely because it depends on a slowly evolving radiobiologic effect on the nerve. Atypical (type 2) and secondary/multiple-sclerosis-related neuralgia respond less reliably than classic type 1 pain.

2.Where SRS sits among TN options

Microvascular decompression (MVD) remains the most durable treatment and is preferred for fit patients with demonstrated neurovascular conflict; percutaneous procedures (radiofrequency rhizotomy, balloon compression, glycerol) offer rapid relief. Radiosurgery is the least invasive option and is particularly suited to elderly or comorbid patients, those on anticoagulation, or those who decline open surgery: accepting the delayed onset and somewhat lower durability in exchange for minimal procedural risk.

3.The Vim lesion without an incision

For essential tremor and tremor-dominant Parkinson disease, a high-dose lesion in the ventral intermediate (Vim) nucleus of the thalamus, typically a single shot through a 4-mm collimator at a maximum dose of 130–150 Gy, with most modern series clustering at 130–140 Gy: can reduce contralateral tremor. It is unilateral, the benefit emerges over months as the lesion matures, and the response is somewhat less predictable per patient than with the alternatives. Its niche is the tremor patient who is not a candidate for awake DBS or for MR-guided focused ultrasound (for example, due to anticoagulation, frailty, or inability to cooperate) since radiosurgical thalamotomy requires no awake testing and no skull-density threshold. Risks include delayed perilesional edema and, uncommonly, an enlarging lesion with sensory or motor deficit. It should be set against DBS, which is adjustable, reversible, and routinely bilateral, and against MRgFUS thalamotomy, which is immediate and lesion-verified and, since FDA approval of the staged bilateral procedure in 2023, no longer confined to one side. Both are covered elsewhere.

4.Epilepsy, OCD, and the cautionary ones

Several other functional applications exist with varying evidence:

• Epilepsy: the randomized ROSE trial compared radiosurgery for mesial temporal lobe epilepsy with anterior temporal lobectomy, treating the amygdalohippocampal complex with 24 Gy to the 50% isodose. Seizure remission at 25–36 months was 52% after radiosurgery and 78% after lobectomy, and radiosurgery did not meet the pre-specified 15% non-inferiority margin, so it remains an alternative for patients who cannot have or decline open surgery rather than an equivalent. SRS is also used for hypothalamic hamartoma, typically at a marginal dose above 17 Gy, and for selected deep or eloquent epileptogenic lesions; its delayed effect and the need for seizure control in the interim are the main limitations, and for hypothalamic hamartoma MR-guided laser interstitial thermal therapy has largely displaced radiosurgery as the first minimally invasive option because it acts immediately.
• Obsessive-compulsive disorder: gamma ventral capsulotomy has sham-controlled support for carefully selected, severe, treatment-refractory OCD, but remains an uncommon intervention delivered only within formal multidisciplinary psychiatric-neurosurgery governance.
• Radiosurgical pallidotomy: largely historical. GPi and STN deep brain stimulation address the full spectrum of parkinsonian symptoms more effectively, and radiosurgical pallidotomy carried a markedly higher complication rate than radiosurgical thalamotomy, reaching 50% in some series, most often contralateral homonymous hemianopia from optic tract exposure or hemiparesis from internal capsule exposure. Without intraoperative physiological confirmation, an oversized or misplaced lesion cannot be detected until the deficit appears.

5.The dose-versus-numbness trade and the modality debate

Functional radiosurgery is built on large single-center series rather than randomized trials, and its controversies center on the trigeminal neuralgia dose and on how SRS compares with the alternatives.

Open controversies:

• Optimal maximum dose. The core trade-off is relief versus numbness: 80–85 Gy favors sensory preservation and ~90 Gy favors durability of relief. ISRS sets 70 Gy as the minimum effective dose and 90 Gy as the maximum effective dose, above which efficacy plateaus while complications rise, but no single optimum within that window commands consensus.
• Target along the nerve. Whether to target the root entry zone or a slightly more distal cisternal segment, and how much nerve length to expose, affects both relief and numbness.
• SRS versus MVD versus percutaneous procedures. SRS is least invasive but slowest and least durable; MVD is most durable for fit patients with neurovascular conflict; the right first choice for an individual patient remains debated.
• Secondary and multiple-sclerosis-related TN. Atypical and MS-related neuralgia respond less reliably than classic type 1 pain: patient selection, not technique, drives much of the variance.